JW Lifescience Balance Sheet Health
Financial Health criteria checks 6/6
JW Lifescience has a total shareholder equity of ₩170.2B and total debt of ₩44.6B, which brings its debt-to-equity ratio to 26.2%. Its total assets and total liabilities are ₩261.9B and ₩91.7B respectively. JW Lifescience's EBIT is ₩34.3B making its interest coverage ratio 41.5. It has cash and short-term investments of ₩55.7B.
Key information
26.2%
Debt to equity ratio
₩44.59b
Debt
| Interest coverage ratio | 41.5x |
| Cash | ₩55.72b |
| Equity | ₩170.20b |
| Total liabilities | ₩91.70b |
| Total assets | ₩261.90b |
Recent financial health updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12
Recent updates
Solid Earnings Reflect JW Lifescience's (KRX:234080) Strength As A Business
Nov 24We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Financial Position Analysis
Short Term Liabilities: A234080's short term assets (₩124.0B) exceed its short term liabilities (₩59.5B).
Long Term Liabilities: A234080's short term assets (₩124.0B) exceed its long term liabilities (₩32.2B).
Debt to Equity History and Analysis
Debt Level: A234080 has more cash than its total debt.
Reducing Debt: A234080's debt to equity ratio has reduced from 38.7% to 26.2% over the past 5 years.
Debt Coverage: A234080's debt is well covered by operating cash flow (125.9%).
Interest Coverage: A234080's interest payments on its debt are well covered by EBIT (41.5x coverage).